Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | SNCA | P37840 | 14/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936516 | 0.91 | HPGD (0.70) | PTGS1PTGS2SNCAHPGDMTNR1A | |
| SCHEMBL9935688 | 0.86 | MTNR1A (0.64) | PTGS1PTGS2SNCAHPGDMTNR1A | |
| SCHEMBL892236 | 0.82 | SNCA (0.61) | PTGS1PTGS2SNCAHPGDMTNR1A | |
| SCHEMBL9942691 | 0.82 | MAPT (0.80) | PTGS1PTGS2SNCAMTNR1AMTNR1B | |
| SCHEMBL892654 | 0.82 | SNCA (0.63) | PTGS1PTGS2SNCAHPGDMTNR1A | |
| SCHEMBL9936475 | 0.81 | SNCA (0.80) | SNCAMAPT | |
| SCHEMBL9936376 | 0.81 | SNCA (0.50) | PTGS1PTGS2SNCAHPGDMTNR1A | |
| SCHEMBL892386 | 0.81 | SNCA (0.61) | PTGS1PTGS2SNCAHPGDMTNR1A | |
| SCHEMBL9935763 | 0.81 | SNCA (0.79) | SNCAHPGDMAPT | |
| SCHEMBL892905 | 0.80 | SNCA (0.58) | PTGS1PTGS2SNCAHPGDMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651887-B1 | N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-9284271-B2 | Compounds for the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-03-15 | — | — | US | disclosed |
| US-9284271-B2 | Compounds for the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-03-15 | — | — | US | disclosed |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-31 | — | — | US | disclosed |
| EP-2651887-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080220-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289033-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | PTGS1 2780/4885PTGS2 3820/4885SNCA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.